Investment Analysts’ Weekly Ratings Updates for Legend Biotech (LEGN)

Legend Biotech (NASDAQ: LEGN) recently received a number of ratings updates from brokerages and research firms:

• 2/4/2026 – Legend Biotech had its price target lowered by analysts at Barclays PLC from $90.00 to $80.00. They now have an “overweight” rating on the stock.
• 1/22/2026 – Legend Biotech was given a new $21.00 price target on by analysts at Jefferies Financial Group Inc..
• 1/22/2026 – Legend Biotech had its “hold” rating reaffirmed by analysts at TD Cowen. They now have a $21.00 price target on the stock, down previously from $62.00.
• 1/22/2026 – Legend Biotech had its price target lowered by analysts at HC Wainwright from $60.00 to $50.00. They now have a “buy” rating on the stock.
• 1/20/2026 – Legend Biotech had its “outperform” rating reaffirmed by analysts at Raymond James Financial, Inc..
• 1/20/2026 – Legend Biotech had its “outperform” rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $66.00 price target on the stock.
• 1/19/2026 – Legend Biotech was upgraded by analysts at Jefferies Financial Group Inc. to a “strong-buy” rating.
• 1/7/2026 – Legend Biotech is now covered by analysts at Oppenheimer Holdings, Inc.. They set an “outperform” rating and a $75.00 price target on the stock.
• 12/29/2025 – Legend Biotech had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/17/2025 – Legend Biotech had its price target lowered by analysts at Cantor Fitzgerald from $75.00 to $74.00. They now have an “overweight” rating on the stock.
• 12/15/2025 – Legend Biotech had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/12/2025 – Legend Biotech had its price target lowered by analysts at Morgan Stanley from $83.00 to $50.00. They now have an “overweight” rating on the stock.

Legend Biotech (NASDAQ: LEGN) is a commercial-stage biopharmaceutical company specializing in the development and commercialization of chimeric antigen receptor T-cell (CAR-T) therapies for oncology. Headquartered in Somerset, New Jersey, with research and development operations in Shanghai, the company leverages a global infrastructure to advance innovative cellular therapies. Legend Biotech pursues a strategy of strategic collaboration to extend its reach, most notably through its partnership with Janssen Biotech, a subsidiary of Johnson & Johnson.

The company’s lead asset, ciltacabtagene autoleucel (commercially marketed as Carvykti), is a B-cell maturation antigen (BCMA)–directed CAR-T therapy for the treatment of relapsed or refractory multiple myeloma.